参考文献/References:
[1]Leopold JA,Maron BA.Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension[J].Int J Mol Sci,2016,17(5):761.
[2]Yandrapalli S,Tariq S,Kumar J,et al.Chronic Thromboembolic Pulmonary Hypertension: Epidemiology,Diagnosis,and Management[J].Cardiol Rev,2018,26(2):62-72.
[3]Fuster V,Steele PM,Edwards WD,et al.Primary pulmonary hypertension: natural history and the importance of thrombosis[J].Circulation,1984,70(4):580-587.
[4]Olschewski H,Rich S.Are anticoagulants still indicated in pulmonary arterial hypertension?[J]Pulmonary circulation,2018,8(4):2045894018807681.
[5]Sarkar P,Mukherjee S,Chai-Coetzer CL,et al.The epidemiology of obstructive sleep apnoea and cardiovascular disease[J].J Thorac Dis,2018,10(Suppl 34):S4189-S4200.
[6]Duluc L,Ahmetaj-Shala B,Mitchell J,et al.Tipifarnib prevents development of hypoxia-induced pulmonary hypertension[J].Cardiovasc Res,2017,113(3):276-287.
[7]Kim M,Alapan Y,Adhikari A,et al.Hypoxia-enhanced adhesion of red blood cells in microscale flow[J].Microcirculation,2017,24(5):10.
[8]Haase VH.Regulation of erythropoiesis by hypoxia-inducible factors[J].Blood Rev,2013,27(1):41-53.
[9]Papageorgiou DP,Abidi SZ,Chang HY,et al.Simultaneous polymerization and adhesion under hypoxia in sickle cell disease[J].Proc Natl Acad Sci U S A,2018,115(38):9473-9478.
[10]Yu Q,Chan SY.Mitochondrial and Metabolic Drivers of Pulmonary Vascular Endothelial Dysfunction in Pulmonary Hypertension[J].Adv Exp Med Biol,2017(967):373-383.
[11]Gao Y,Chen T,Raj JU.Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension[J].Am J Respir Cell Mol Biol,2016,54(4):451-460.
[12]Alvarez RA,Miller MP,Hahn SA,et al.Targeting Pulmonary Endothelial Hemoglobin α Improves Nitric Oxide Signaling and Reverses Pulmonary Artery Endothelial Dysfunction[J].Am J Respir Cell Mol Biol,2017,57(6):733-744.
[13]Jaitovich A,Jourd'heuil D.A Brief Overview of Nitric Oxide and Reactive Oxygen Species Signaling in Hypoxia-Induced Pulmonary Hypertension[J].Adv Exp Med Biol,2017(967):71-81.
[14]Forte M,Conti V,Damato A,et al.Targeting Nitric Oxide with Natural Derived Compounds as a Therapeutic Strategy in Vascular Diseases[J].Oxid Med Cell Longev,2016(2016):7364138.
[15]Chester AH,Yacoub MH,Moncada S.Nitric oxide and pulmonary arterial hypertension[J].Glob Cardiol Sci Pract,2017,2017(2):14.
[16]Liu Q,Hu H,Hu T,et al.STVNa attenuates right ventricle hypertrophy and pulmonary artery remodeling in rats induced by transverse aortic constriction[J].Biomed Pharmacother, 2018(101):371-378.
[17]Joy NG,Mikeladze M,Younk LM,et al.Effects of equivalent sympathetic activation during hypoglycemia on endothelial function and pro-atherothrombotic balance in healthy individuals and obese standard treated type 2 diabetes[J].Metabolism,2016,65(12):1695-1705.
[18]Srihirun S,Tanjararak N,Chuncharunee S,et al. Platelet hyperactivity in thalassemia patients with elevated tricuspid regurgitant velocity and the association with hemolysis[J].Thromb Res,2015,135(1):121-126.
[19]Li XF,Song CH,Sheng HZ,et al.P-selectin gene polymorphism associates with pulmonary hypertension in congenital heart disease[J].Int J Clin Exp Pathol,2015,8(6):7189-7195.
[20]Fayed MA,Abdel-Hady HE,Hafez MM,et al.Study of platelet activation, hypercoagulable state, and the association with pulmonary hypertension in children with β-thalassemia[J].Hematol Oncol Stem Cell Ther,2018,11(2):65-74.
[21]Yamaguchi J,Hara N,Yamaguchi T,et al.Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin Ⅲ deficiency[J].J Cardiol Cases,2017,16(5): 144-147.
[22]D'Agostino C,Zonzin P,Enea I,et al.ANMCO Position Paper:long-term follow-up of patients with pulmonary thromboembolism[J].Eur Heart J Suppl,2017,19(Suppl D):D309-D332.
[23]Rabinovitch M,Guignabert C,Humbert M,et al.Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension[J].Circ Res,2014,115(1):165-175.
[24]Gupta N,Sahu A,Prabhakar A,et al.Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Systemic Inflammation in Patients with Idiopathic Pulmonary Arterial Hypertension[J].Med Sci Monit,2019(25):746-753.
[25]Mickael CS,Graham BB.The Role of Type 2 Inflammation in Schistosoma-Induced Pulmonary Hypertension[J].Front Immunol,2019(10):27.
[26]Tielemans B,Delcroix M,Belge C,et al.TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension[J].Drug Discov Today,2019,24(3):703-716.
[27]Fu J,Chen YF,Zhao X,et al.Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates monocrotaline-induced pulmonary vascular remodeling[J].Arterioscler Thromb Vasc Biol,2014,34(7):1539-1547.
[28]Hashimoto-Kataoka T,Hosen N,Sonobe T,et al.Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension[J].Proc Natl Acad Sci U S A, 2015,112(20):E2677-E2686.
[29]Gupta N,Sahu A,Prabhakar A,et al.Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia[J].Proc Natl Acad Sci U S A,2017,114(18):4763-4768.
[30]Bester J,Pretorius E.Effects of IL-1β,IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity[J].Sci Rep,2016(6):32188.
[31]Duan J,Liang S,Yu Y,et al.Inflammation-coagulation response and thrombotic effects induced by silica nanoparticles in zebrafish embryos[J].Nanotoxicology,2018,12(5):470-484.
[32]van Uden D,Boomars K,Kool M.Dendritic Cell Subsets and Effector Function in Idiopathic and Connective Tissue Disease-Associated Pulmonary Arterial Hypertension[J].Front Immunol,2019:10-11.
[33]Sweatt AJ,Hedlin HK,Balasubramanian V,et al.Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension[J].Circ Res,2019,124(6):904-919.
[34]Duong H,Bonham CA.Sarcoidosis-associated Pulmonary Hypertension:Pathophysiology,Diagnosis, and Treatment[J].Clin Pulm Med,2018,25(2):52-60.
[35]Odler B,Foris V,Gungl A,et al.Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach[J].Front Physiol,2018(9):587.
相似文献/References:
[1]周婷婷,万毅新.巨大肺动脉瘤伴重度肺动脉高压1例并文献复习[J].医学信息,2018,31(03):191.[doi:10.3969/j.issn.1006-1959.2018.03.073]
ZHOU Ting-ting,WAN Yi-xin.Giant Pulmonary Aneurysm with Severe Pulmonary Hypertension:a Case Report and Literature Review[J].Journal of Medical Information,2018,31(09):191.[doi:10.3969/j.issn.1006-1959.2018.03.073]
[2]马 麟,廖宝兰,钟周华.超声心动图诊断老年冠心病患者肺动脉高压的临床价值分析[J].医学信息,2018,31(21):173.[doi:10.3969/j.issn.1006-1959.2018.21.051]
MA Lin,LIAO Bao-lan,ZHONG Zhou-hua.Clinical Value of Echocardiography in Diagnosis of Pulmonary Hypertension in Elderly Patients with Coronary Heart Disease[J].Journal of Medical Information,2018,31(09):173.[doi:10.3969/j.issn.1006-1959.2018.21.051]
[3]韩婷婷,王 虹,吴美美,等.N-proBNP对慢性心衰患者发生肺动脉高压的预测价值[J].医学信息,2019,32(05):114.[doi:10.3969/j.issn.1006-1959.2019.05.035]
HAN Ting-ting,WANG Hong,WU Mei-mei,et al.Predictive Value of N-proBNP for Pulmonary Hypertension in Patients with Chronic Heart Failure[J].Journal of Medical Information,2019,32(09):114.[doi:10.3969/j.issn.1006-1959.2019.05.035]
[4]冉瑞图,苏 帅,唐先圣,等.影响PCNL术后出血栓塞治疗的主要因素分析[J].医学信息,2019,32(11):124.[doi:10.3969/j.issn.1006-1959.2019.11.036]
RAN Rui-tu,SU Shuai,TANG Xian-sheng,et al.Analysis of Main Factors Affecting Thromboembolism After PCNL[J].Journal of Medical Information,2019,32(09):124.[doi:10.3969/j.issn.1006-1959.2019.11.036]
[5]曹雪芹,胡文媛,李 娟,等.妊娠合并肺动脉高压严重程度对围生期结局的影响[J].医学信息,2019,32(16):58.[doi:10.3969/j.issn.1006-1959.2019.16.018]
CAO Xue-qin,HU Wen-yuan,LI Juan,et al.Effect of Severity of Pregnancy with Pulmonary Hypertension on Perinatal Outcome[J].Journal of Medical Information,2019,32(09):58.[doi:10.3969/j.issn.1006-1959.2019.16.018]
[6]李宜桐,李 勇.低氧性肺动脉高压肺血管重塑机制的研究[J].医学信息,2020,33(15):26.[doi:10.3969/j.issn.1006-1959.2020.15.010]
LI Yi-tong,LI Yong.Research on Mechanism of Pulmonary Vascular Remodeling in Hypoxic Pulmonary Hypertension[J].Journal of Medical Information,2020,33(09):26.[doi:10.3969/j.issn.1006-1959.2020.15.010]
[7]李佳霖,张 维.红花黄色素注射液对AECOPD合并肺动脉高压患者血流动力学和氧化应激的影响[J].医学信息,2020,33(17):54.[doi:10.3969/j.issn.1006-1959.2020.17.016]
LI Jia-lin,ZHANG Wei.Effects of Safflower Yellow Injection on Hemodynamics and Oxidative Stress in Patients with AECOPD Complicated with Pulmonary Hypertension[J].Journal of Medical Information,2020,33(09):54.[doi:10.3969/j.issn.1006-1959.2020.17.016]
[8]赵丽红,蒋 萍.IPAF患者的临床特点及预后分析[J].医学信息,2021,34(15):119.[doi:10.3969/j.issn.1006-1959.2021.15.031]
ZHAO Li-hong,JIANG Ping.Clinical Characteristics and Prognostic Analysis of Patients with Interstitial Pneumonia with Autoimmune Characteristics[J].Journal of Medical Information,2021,34(09):119.[doi:10.3969/j.issn.1006-1959.2021.15.031]
[9]郑合清.老年慢性支气管炎的中西医治疗[J].医学信息,2021,34(16):57.[doi:10.3969/j.issn.1006-1959.2021.16.016]
ZHENG He-qing.Treatment of Chronic Bronchitis in the Elderly with Traditional Chinese Medicine and Western Medicine[J].Journal of Medical Information,2021,34(09):57.[doi:10.3969/j.issn.1006-1959.2021.16.016]
[10]肖作川.心脏超声对肺动脉高压患者肺动脉压及右心功能的评估价值[J].医学信息,2023,36(24):136.[doi:10.3969/j.issn.1006-1959.2023.24.031]
XIAO Zuo-chuan.Value of Echocardiography in Evaluating Pulmonary Artery Pressure and Right Ventricular Function in Patients with Pulmonary Hypertension[J].Journal of Medical Information,2023,36(09):136.[doi:10.3969/j.issn.1006-1959.2023.24.031]